MEXICO CITY — It’s mentioned to be the closest the world has come to a vaccine towards the AIDS virus.
The twice-yearly shot was 100% efficient in stopping HIV infections in a research in girls, and outcomes launched Wednesday present it labored virtually as nicely in males.
Drugmaker Gilead mentioned it’s going to enable low-cost, generic variations to be offered in 120 poor international locations with excessive HIV charges, primarily in Africa, Southeast Asia and the Caribbean. Nevertheless it has excluded virtually all of Latin America, the place charges are a lot decrease however rising, elevating considerations that the world is lacking a vital alternative to cease the illness.
“That is so superior to another prevention methodology we’ve got, it's unprecedented,” mentioned Winnie Byanyima, government director of UNAIDS. He credited Gilead for growing the drug, however mentioned the world's skill to cease AIDS relies on its use in at-risk international locations.
In a report launched Sunday to mark World AIDS Day, UNAIDS mentioned the variety of AIDS deaths final yr – about 630,000 folks – was the bottom since its peak in 2004, suggesting the world is now at “a historic crossroads” and has an opportunity to finish the epidemic.
The drug referred to as lenacapavir is already offered beneath the model identify Sunlenca to deal with HIV infections in america, Canada, Europe and elsewhere. The corporate plans to quickly apply for authorization to make use of Sunlenca for HIV prevention.
Whereas there are different methods to guard towards infections, resembling condoms, day by day tablets, vaginal rings and bimonthly injections, consultants say Gilead's bimonthly injections could be significantly useful for marginalized people who find themselves usually afraid to hunt care, together with homosexual males. . employees and younger girls.
“It might be a miracle for these teams as a result of it means they solely have to point out up twice a yr at a clinic after which they’re protected,” mentioned Byanyima of UNAIDS.
Such was the case of Luis Ruvalcaba, a 32-year-old man from Guadalajara, Mexico, who participated within the newest revealed research. He mentioned he was afraid to ask for the day by day prevention tablets offered by the federal government, for worry of being discriminated towards for being a homosexual man. As a result of he participated within the research, he’ll proceed receiving the injections for no less than one other yr.
“In Latin American international locations there may be nonetheless numerous stigma, sufferers are embarrassed to ask for tablets,” mentioned Dr. Alma Minerva Pérez, who recruited and enrolled a dozen volunteers for the research at a personal analysis middle in Guadalajara.
It isn’t but recognized how extensively the vaccines will probably be out there in Mexico by the nation's well being care system. Well being officers declined to touch upon any plans to buy Sunlenca for his or her residents; In 2021, day by day tablets to stop HIV turned freely out there by the nation's public well being system.
“If the potential of utilizing generics has been opened, I’ve religion that Mexico can take part,” mentioned Pérez.
A pharmacist holds a vial of lenacapavir, the brand new injectable HIV prevention drug, on the Desmond Tutu Well being Basis's Masiphumelele analysis website in Cape City, South Africa.
AP Picture/Nardus Engelbrecht, File
Byanyima mentioned international locations apart from Mexico that participated within the investigation have been additionally excluded from the generic deal, together with Brazil, Peru and Argentina. “To disclaim them that drug now’s extreme.” she mentioned.
In a press release, Gilead mentioned it has “an ongoing dedication to assist allow entry to HIV prevention and therapy choices the place the necessity is biggest.” Among the many 120 international locations eligible for the generic model are 18 international locations, largely African, representing 70% of the worldwide HIV burden.
The pharmaceutical firm mentioned it’s also working to ascertain “speedy and environment friendly pathways to succeed in all individuals who want or need lenacapavir for HIV prevention.”
On Thursday, 15 advocacy teams in Peru, Argentina, Ecuador, Chile, Guatemala and Colombia wrote to Gilead, calling for generic Sunlenca to be made out there in Latin America, citing the “alarming” inequality in entry to new HIV prevention instruments whereas that an infection charges have been rising.
Whereas international locations together with Norway, France, Spain and america have paid greater than $40,000 a yr for Sunlenca, consultants have estimated it might be produced for as little as $40 per therapy as soon as generic manufacturing expands to cowl 10 million. of individuals.
Dr. Chris Beyrer, director of the Duke College International Well being Institute, mentioned it is going to be enormously useful to have Sunlenca out there within the hardest-hit international locations in Africa and Asia. However he mentioned rising charges of HIV amongst teams together with homosexual males and transgender populations constituted “a public well being emergency” in Latin America.
Hannya Danielle Torres, a 30-year-old trans girl and artist who was on the Sunlenca studio in Mexico, mentioned she hoped the federal government would discover a approach to supply the injections. “Mexico might have among the richest folks on the earth, but it surely additionally has among the most weak folks residing in excessive poverty and violence,” Torres mentioned.
One other drugmaker, Viiv Healthcare, additionally neglected most of Latin America when it allowed generics of its HIV prevention vaccine in about 90 international locations. Bought as Apretude, the bimonthly injections are 80% to 90% efficient in stopping HIV. They price about $1,500 a yr in middle-income international locations, greater than most can afford.
Asia Russell, government director of advocacy group Well being Hole, mentioned that with greater than 1 million new HIV infections annually worldwide, established prevention strategies will not be sufficient. He urged international locations like Brazil and Mexico to difficulty “obligatory licenses,” a mechanism by which international locations droop patents within the occasion of a well being disaster.
It's a method that some international locations adopted for earlier HIV therapies, together with within the late 1990s and 2000s, when AIDS medicine have been first found. Extra just lately, Colombia issued its first obligatory license for key HIV therapy Tivicay in April, with out the permission of its drugmaker, Viiv.
Dr. Salim Abdool Karim, an AIDS professional on the College of KwaZulu-Natal in South Africa, mentioned he had by no means seen a drug that gave the impression to be as efficient as Sunlenca in stopping HIV.
“The lacking piece of the puzzle now’s how you can get it to everybody who wants it,” he mentioned.
___
Cheng reported from London.
___
The Related Press Well being and Science Division receives help from the Howard Hughes Medical Institute's Science and Instructional Media Group. The AP is solely accountable for all content material.
Copyright © 2024 by The Related Press. All rights reserved.